IMV Inc. Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug Reata Pharmaceuticals, Inc.

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Analysts predict that IMV Inc. (NASDAQ:IMV) will announce ($0.13) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for IMVs earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.11). IMV posted earnings per share of ($0.11) in the same quarter last year, which indicates a negative []

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and blood cancers, today announced new translational data implicating B cells in the clinical benefit induced by MVP-S treatment in ovarian cancer patients. These data will be showcased at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) congress, December 8-1

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and blood cancers while preserving patients quality of life, today announced that the first patient with hormone receptor positive/HER2-negative (HR+/HER2-) breast cancer has been dosed with its lead compound, maveropepimut-S (MVP-S, formerly known as DPX-Survivac). In this tria

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cance

(RTTNews) - Biotechnology company IMV Inc. (IMV, IMV.TO) announced Monday that Chief Financial Officer Pierre Labbe will retire on March 31, 2022. The Company has retained an executive search firm and Labbe will continue to consult with IMV to support the transition after his retirement. Labbe has been CFO since February 2017. Before joining

Brokerages forecast that IMV Inc. (NASDAQ:IMV) will announce earnings per share of ($0.13) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for IMVs earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.14). IMV reported earnings per share of ($0.11) in the []

IMV (TSE:IMV) had its price objective reduced by National Bankshares from C$4.25 to C$2.50 in a research note published on Friday, BayStreet.CA reports. National Bankshares currently has a sector perform rating on the stock. A number of other brokerages have also recently issued reports on IMV. National Bank Financial reissued a sector perform market weight []

IMV Inc. (IMV) CEO Q3 2021 Results - Earnings Call Transcript

DARTMOUTH, Nova Scotia, and CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunoth

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunoth

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunoth